﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 13:39:19 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Delisting of the shares of Dignitana: last day of trading 24 June 2025</title><link>https://news.cision.com/dignitana-ab/r/delisting-of-the-shares-of-dignitana--last-day-of-trading-24-june-2025,c4161536</link><guid isPermaLink="false">cision5068415</guid><description><![CDATA[In accordance with Nasdaq Stockholm AB’s decision following application from the board of directors of Dignitana AB, the shares of Dignitana will be delisted from Nasdaq First North Growth Market. The last day of trading is 24 June 2025.]]></description><pubDate>Tue, 10 Jun 2025 15:28:55 GMT</pubDate></item><item><title>Dignitana applies for delisting</title><link>https://news.cision.com/dignitana-ab/r/dignitana-applies-for-delisting,c4159310</link><guid isPermaLink="false">cision5067968</guid><description><![CDATA[The outcome of the extended acceptance period in the public takeover offer from Paxman AB (publ) (“Paxman”) regarding Dignitana AB (“Dignitana”) was announced by Paxman on 2 June 2025. Paxman controls more than 90 percent of the shares and votes in Dignitana and has initiated a compulsory acquisition procedure in respect of the remaining shares in Dignitana.

 

The board of directors of Dignitana has, at the request of Paxman, today resolved to apply for delisting of Dignitana’s shares from Nasdaq First North Growth Market. The last day of trading in Dignitana’s shares on Nasdaq First]]></description><pubDate>Tue, 10 Jun 2025 07:40:31 GMT</pubDate></item><item><title>Bulletin from the Extraordinary General Meeting of Dignitana AB (publ)</title><link>https://news.cision.com/dignitana-ab/r/bulletin-from-the-extraordinary-general-meeting-of-dignitana-ab--publ-,c4159710</link><guid isPermaLink="false">cision5066176</guid><description><![CDATA[The following resolutions were passed at the Extraordinary General Meeting (the “EGM”) of Dignitana AB (publ) (the “Company”) on 5 June 2025 in Lund.

 

Board of Directors

The EGM resolved, in accordance with the proposal from the shareholder Paxman AB (publ), that the Board of Directors shall consist of three ordinary members with no deputy Board members. Furthermore, the EGM resolved to dismiss the Board members Klas Arildsson, Richard DiIorio, Lina Karlsson, Fredrik Lindgren, and Hope S. Rugo, MD. The EGM also resolved to elect Per-Anders Johansson, Richard Paxman, and Emelie]]></description><pubDate>Thu, 05 Jun 2025 08:58:06 GMT</pubDate></item><item><title>Dignitana AB Publishes Q1 2025 Interim Report</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q1-2025-interim-report,c4153961</link><guid isPermaLink="false">cision5057965</guid><description><![CDATA[Increased turnover – closing in on positive result

.

Financial highlights Q1 2025

  · Net Sales amounted to 22.0 MSEK (21.2), an increase of 4 percent over the same quarter in 2024.
  · Operating Result amounted to -1.6 MSEK (-5.0).
  · Net Result after financial items amounted to -1.9 MSEK (-5.1).
  · EBITDA for the first quarter is positive at 0.8 MSEK   (-1.1).
  · Earnings per share were –0.02 SEK (-0.07).
  · Cash Balance amounted to 2.8 MSEK (2.8).
  · Average Daily Treatment Revenue (ADTR)* was 268 TSEK (241) in the quarter

Business highlights during the period]]></description><pubDate>Thu, 22 May 2025 06:15:20 GMT</pubDate></item><item><title>NOTICE OF ANNUAL GENERAL MEETING IN DIGNITANA AB (publ)</title><link>https://news.cision.com/dignitana-ab/r/notice-of-annual-general-meeting-in-dignitana-ab--publ-,c4153948</link><guid isPermaLink="false">cision5057916</guid><description><![CDATA[NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.

 

NOTICE OF ANNUAL GENERAL MEETING IN DIGNITANA AB (publ)

 

The shareholders of Dignitana AB (publ) reg. no. 556730-5346 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 26 June 2025 at 10.00 CEST at the Company’s premises, Traktorgränd 3, 226 60 in Lund. Entry registration for the AGM will commence at 09.30 CEST.

 

Right to participate

Shareholders that wish to participate in the AGM shall be]]></description><pubDate>Thu, 22 May 2025 06:00:00 GMT</pubDate></item><item><title>Notice of Extraordinary General Meeting in Dignitana AB (publ)</title><link>https://news.cision.com/dignitana-ab/r/notice-of-extraordinary-general-meeting-in-dignitana-ab--publ-,c4151957</link><guid isPermaLink="false">cision5055069</guid><description><![CDATA[NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.

 

The shareholders of Dignitana AB (publ) reg. no. 556730-5346 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the “EGM”) on 5 June 2025 at 10.00 CEST at the Company’s premises, Traktorgränd 3, 226 60 in Lund. Entry registration for the EGM will commence at 09.30 CEST.

 

The EGM is convened at the request of the shareholder Paxman AB (publ) (the “Shareholder”) holding more than ten (10) percent of the number of]]></description><pubDate>Mon, 19 May 2025 06:01:58 GMT</pubDate></item><item><title>Dignitana postpones Annual General Meeting</title><link>https://news.cision.com/dignitana-ab/r/dignitana-postpones-annual-general-meeting,c4136786</link><guid isPermaLink="false">cision5033553</guid><description><![CDATA[Dignitana AB (publ) (”Dignitana”) announces that the date for Dignitana’s Annual General Meeting (the ”AGM”) has been postponed to 26 June 2025 in light of the ongoing public takeover offer from Paxman.

 

Due to the ongoing public takeover offer from Paxman, the Board of Directors of Dignitana has resolved to postpone the AGM, which was previously planned for 22 May 2025. The new date for Dignitana’s AGM is 26 June 2025.

 

For more information about the ongoing public takeover offer, please see the offer document available on Paxman’s website via the following link (https://www.]]></description><pubDate>Wed, 16 Apr 2025 08:33:08 GMT</pubDate></item><item><title>Statement by the Board of Directors of Dignitana regarding the public offer from Paxman</title><link>https://news.cision.com/dignitana-ab/r/statement-by-the-board-of-directors-of-dignitana-regarding-the-public-offer-from-paxman,c4120132</link><guid isPermaLink="false">cision5009301</guid><description><![CDATA[The Board of Directors unanimously recommends the shareholders to accept the offer.

This statement is made by the Board of Directors of Dignitana AB (“Dignitana” or the “Company”) pursuant to Rule II.19 of the Stock Market Self-Regulation Committee’s takeover rules for certain trading platforms (the “Takeover Rules”).

 

The Offer

Today, 18 March 2025, Paxman AB (publ) (“Paxman” or the “Offeror”) announced a public offer to the shareholders of Dignitana to transfer all shares in Dignitana to Paxman in exchange for consideration in the form of approximately 0.0308[1] newly issued]]></description><pubDate>Tue, 18 Mar 2025 07:02:00 GMT</pubDate></item><item><title>Dignitana AB Publishes Q4 2024 Interim Report</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q4-2024-interim-report,c4108583</link><guid isPermaLink="false">cision4993109</guid><description><![CDATA[Strong finish to 2024 – record high sales in Q4

Financial highlights Q4 2024

  · Net Sales amounted to 24.0 MSEK (21.3), an increase of 13 percent over the same quarter in 2023.
  · Operating Result amounted to -1.6 MSEK (-3.7).
  · Net Result after financial items amounted to -1.1 MSEK (-4.9).
  · EBITDA for the Fourth Quarter is positive at 1.1 MSEK (0.1).
  · Earnings per share were -0.01 SEK (-0.07).
  · Cash Balance amounted to 3.0 MSEK (6.0).
  · Average Daily Treatment Revenue (ADTR)* was 251 TSEK (238) in the quarter.

Financial highlights Full Year 2024

  · Net]]></description><pubDate>Thu, 20 Feb 2025 07:00:00 GMT</pubDate></item><item><title>Dignitana to address MedTech innovation at Texas BioLife Summit</title><link>https://news.cision.com/dignitana-ab/r/dignitana-to-address-medtech-innovation-at-texas-biolife-summit,c4107905</link><guid isPermaLink="false">cision4992100</guid><description><![CDATA[Dignitana will join MedTech leaders speaking at the Texas BioLife Summit (https://www.biolifesummits.com/texas-biolife-summit) in Dallas on February 27, 2025.

Melissa Bourestom, Dignitana Chief Communications Officer, is featured on a panel titled “Devices and Diagnostics: Where Health and Innovation Meet.” The session will focus on the rise of innovation leading to the development of highly impactful medical devices and diagnostic tools that can be used to both identify and combat an array of health problems. Panelists will discuss challenges they’ve faced and how to overcome them, as]]></description><pubDate>Wed, 19 Feb 2025 07:50:13 GMT</pubDate></item><item><title>Dignitana expands intellectual property with new patent in Korea</title><link>https://news.cision.com/dignitana-ab/r/dignitana-expands-intellectual-property-with-new-patent-in-korea,c4107086</link><guid isPermaLink="false">cision4991068</guid><description><![CDATA[Dignitana (http://www.dignitana.com/) has received a Notice of Allowance from the Korean Intellectual Property Office for a patent titled “Scalp Cooling Apparatus, Method and System.”

Patent Application No. 10-2021-7017704 was submitted in 2021 and approved 31 December 2024.  This filing expands on the previous Korean patent obtained by Dignitana in 2014 which was based on technology in Dignitana’s legacy C3 DigniCap scalp cooling system.

“Dignitana's IP portfolio provides a broad protection for our scalp cooling technology. We have an active IP strategy and have consistently worked]]></description><pubDate>Tue, 18 Feb 2025 07:00:00 GMT</pubDate></item><item><title>Chronos Trade Medical joins Dignitana as exclusive distributor in Romania</title><link>https://news.cision.com/dignitana-ab/r/chronos-trade-medical-joins-dignitana-as-exclusive-distributor-in-romania,c4106428</link><guid isPermaLink="false">cision4990284</guid><description><![CDATA[Dignitana (http://www.dignitana.com/) has signed a Distribution Agreement for Chronos Trade Medical (https://chronostrade.ro) to be the exclusive provider of The DigniCap Scalp Cooling System in Romania. DigniCap is an innovative medical device clinically proven to minimize hair loss from chemotherapy.

Chronos has purchased two DigniCap Delta systems to initiate sales in the Romania and will attend Distributor Training at the Dignitana office in Lund.

“With breast cancer as the leading cancer among women in Romania, there is strong demand to address the side effect of hair loss from]]></description><pubDate>Mon, 17 Feb 2025 07:08:14 GMT</pubDate></item><item><title>Dignitana announces legislation signed to require insurance coverage for New York patients using scalp cooling to preserve hair during chemotherapy</title><link>https://news.cision.com/dignitana-ab/r/dignitana-announces-legislation-signed-to-require-insurance-coverage-for-new-york-patients-using-sca,c4082442</link><guid isPermaLink="false">cision4957846</guid><description><![CDATA[Dignitana (http://www.dignitana.com/) announces that New York Governor Kathy Hochul has signed a bill to provide insurance coverage for scalp cooling systems used to preserve hair during chemotherapy treatment for cancer. The act will take effect January 1, 2026.

With this legislation (A38-A/S2063-A (https://www.nysenate.gov/legislation/bills/2023/S2063/amendment/A#:~:text=2023%2DS2063%20%2D%20Summary,hair%20during%20cancer%20chemotherapy%20treatment.)), New York becomes the first state in the U.S. to require private health insurers to provide coverage for these devices. The bill,]]></description><pubDate>Mon, 16 Dec 2024 07:00:20 GMT</pubDate></item><item><title>Dignitana signs Boosst as exclusive distributor in Ecuador and Peru</title><link>https://news.cision.com/dignitana-ab/r/dignitana-signs-boosst-as-exclusive-distributor-in-ecuador-and-peru,c4081564</link><guid isPermaLink="false">cision4956643</guid><description><![CDATA[Dignitana (http://www.dignitana.com/) has signed a Distribution Agreement for Boosst to be the exclusive provider of The DigniCap Scalp Cooling System in Ecuador and Peru. Initiating the agreement, Boosst has purchased two DigniCap Delta devices which will be delivered this month and used at Life & Hope Specialty Care in Quito. DigniCap is an innovative medical device used by cancer centers to minimize hair loss from chemotherapy.

Christian Frison, CEO of Boosst,  said, “I am excited to offer this cutting-edge technology to cancer centers, giving patients a way to maintain dignity and]]></description><pubDate>Thu, 12 Dec 2024 13:31:19 GMT</pubDate></item><item><title>Dignitana AB Publishes Q3 2024 Interim Report</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q3-2024-interim-report,c4069511</link><guid isPermaLink="false">cision4943074</guid><description><![CDATA[More progress in reimbursement

Financial highlights Q3 2024

  · Net Sales amounted to 22.8 MSEK (22.2), an increase of 3 percent over the same quarter in 2023.
  · Operating Result amounted to -0.7 MSEK (-3.2).
  · Net Result after financial items amounted to -1.5 MSEK (-3.7).
  · EBITDA for the third quarter is positive at 2.1 MSEK (0.7).
  · Earnings per share were -0.02 SEK (-0.05).
  · Cash Balance amounted to 4.4 MSEK (7.0).
  · Average Daily Treatment Revenue (ADTR)* was 231 TSEK (237) in the quarter.

Business highlights during the period)

  · In August Dignitana]]></description><pubDate>Thu, 21 Nov 2024 07:30:00 GMT</pubDate></item><item><title>Dignitana AB (publ) appoints Nomination Committee for Annual General Meeting 2025</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab--publ--appoints-nomination-committee-for-annual-general-meeting-2025,c4067569</link><guid isPermaLink="false">cision4940533</guid><description><![CDATA[The Dignitana Annual General Meeting 2025 will be held on 22 May 2025. The Nomination Committee for the Dignitana Annual General Meeting 2025 consists of:

  · Greg Dingizian, Chairman of the Board and Owner of Agartha AB on closely related company's mandate  
  · Magnus Sjöqvist, Swedbank Robur Fonder AB on closely related company mandate
  · Bill Cronin, UBS Financial Services Inc. on closely related company mandate
  · Klas Arildsson, Chairman of the Board

The Nomination Committee shall give proposals for Chairman at the AGM, election, and remuneration of board members and, where]]></description><pubDate>Mon, 18 Nov 2024 08:00:00 GMT</pubDate></item><item><title>University Hospital Schleswig-Holstein in Kiel, Germany selects DigniCap</title><link>https://news.cision.com/dignitana-ab/r/university-hospital-schleswig-holstein-in-kiel--germany-selects-dignicap,c4065647</link><guid isPermaLink="false">cision4937649</guid><description><![CDATA[Dignitana AB (http://www.dignitana.com/) announces that the highly ranked University Hospital Schleswig-Holstein (http://www.unifrauenklinik-kiel.de/) (UKSH) in Kiel, Germany will offer DigniCap for patients at the Clinic for Gynecology and Obstetrics.

The clinic acquired two DigniCap Delta devices and the staff completed the training in October. UKSH chose DigniCap based on the advanced technology in the DigniCap Delta device which is designed to improve patient outcomes and ease of use.

“UKSH offers patients comprehensive cancer care with the most advanced diagnostics and treatments.]]></description><pubDate>Wed, 13 Nov 2024 07:01:33 GMT</pubDate></item><item><title>Method for Scalp Cooling Now Offered to More Patients – Reduces Hair Loss in Cancer Patients</title><link>https://news.cision.com/dignitana-ab/r/method-for-scalp-cooling-now-offered-to-more-patients---reduces-hair-loss-in-cancer-patients,c4062761</link><guid isPermaLink="false">cision4935621</guid><description><![CDATA[The Aleris Oncology Clinic at Sabbatsberg Hospital, Stockholm - Sweden is expanding access to an innovative scalp cooling treatment for cancer patients after a successful pilot project in collaboration with Dignitana.

 

“We have observed improvements in our patients’ psychosocial well-being,” says Anna-Maria Hasselgren Häll, oncology nurse at Aleris Christinakliniken.

 

Aleris has conducted a series of extensive trials on an innovative scalp cooling treatment that reduces hair loss in cancer patients undergoing chemotherapy for solid tumors. Patients beginning chemotherapy will]]></description><pubDate>Mon, 11 Nov 2024 09:09:46 GMT</pubDate></item><item><title>Dignitana announces 40 percent increase in 2025 average rate for scalp cooling reimbursement by US Centers for Medicare and Medicaid Services</title><link>https://news.cision.com/dignitana-ab/r/dignitana-announces-40-percent-increase-in-2025-average-rate-for-scalp-cooling-reimbursement-by-us-c,c4061318</link><guid isPermaLink="false">cision4932016</guid><description><![CDATA[Dignitana AB announces today that the US Centers for Medicare & Medicaid Services (CMS) has published the OPPS Final Rule (https://public-inspection.federalregister.gov/2024-25521.pdf) with an increase in the average rate for CPT® 0662T from $1250.50 to $1750.50 under the Hospital Outpatient Prospective Payment System (OPPS) and the Ambulatory Surgery Center (ASC) payment system for Calendar Year (CY) 2025.

This is a 39.98 percent increase from the 2024 rate and is also higher than the rate posted earlier this year in the 2025 CMS Proposed Rule.

“This is another strong step forward]]></description><pubDate>Tue, 05 Nov 2024 08:44:10 GMT</pubDate></item><item><title>Dignitana enhances customer support with InfuSystem field service partnership</title><link>https://news.cision.com/dignitana-ab/r/dignitana-enhances-customer-support-with-infusystem-field-service-partnership,c4057197</link><guid isPermaLink="false">cision4926218</guid><description><![CDATA[Scalp cooling innovator Dignitana AB (http://www.dignitana.com/) announces today the expansion of the company’s partnership with InfuSystem Holdings, Inc., (http://www.infusystem.com/) to include field service support of The DigniCap Scalp Cooling System in U.S. chemotherapy infusion centers.

As part of the Field Service Agreement, certified InfuSystem Field Specialists will provide biomedical services which include telephone support, repair solutions and annual preventive maintenance to DigniCap providers in the United States.  Service will be conducted on-site at the facility and off-]]></description><pubDate>Mon, 28 Oct 2024 07:00:00 GMT</pubDate></item><item><title>Dignitana Announces New CPT® Category I Codes from the American Medical Association for Mechanical Scalp Cooling</title><link>https://news.cision.com/dignitana-ab/r/dignitana-announces-new-cpt--category-i-codes-from-the-american-medical-association-for-mechanical-s,c4053605</link><guid isPermaLink="false">cision4920954</guid><description><![CDATA[Dignitana announces that three CPT® Category I codes for mechanical scalp cooling have been issued by the American Medical Association as listed in the September 2024: CPT (https://www.ama-assn.org/system/files/sept-2024-summary-of-panel-actions.pdf)® (https://www.ama-assn.org/system/files/september-2023-cpt-summary-panel-actions.pdf) Editorial Summary of Panel Actions (https://www.ama-assn.org/system/files/sept-2024-summary-of-panel-actions.pdf) that was posted today.  The updated AMA code set will be released Fall 2025 and will take effect on January 1, 2026. This is a very positive]]></description><pubDate>Fri, 18 Oct 2024 14:57:09 GMT</pubDate></item><item><title>Dignitana AB announces PDMR transaction</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab-announces-pdmr-transaction,c4050395</link><guid isPermaLink="false">cision4916616</guid><description><![CDATA[Dignitana AB (http://www.dignitana.com/) announces that Dignitana Board member Fredrik Lindgren purchased 1 500 000 Dignitana AB shares in a PDMR transaction on 8 October 2024.]]></description><pubDate>Fri, 11 Oct 2024 14:13:52 GMT</pubDate></item><item><title>Information on PDMR transactions in Dignitana AB</title><link>https://news.cision.com/dignitana-ab/r/information-on-pdmr-transactions-in-dignitana-ab,c4029017</link><guid isPermaLink="false">cision4887981</guid><description><![CDATA[Dignitana AB announces PDMR transactions in the Company’s share with three purchases made by Dignitana leadership and board members on 22 and 23 August following publication of the Q2 Interim Report.

Dignitana CEO Fredrik Jonsson purchased 50,000 shares, Chairman of the Board of Directors Klas Arildsson purchased 50,000 shares, and Board member Fredrik Lindgren purchased 143,511 shares.]]></description><pubDate>Tue, 27 Aug 2024 08:57:26 GMT</pubDate></item><item><title>Dignitana AB Publishes Q2 2024 Interim Report</title><link>https://news.cision.com/dignitana-ab/r/dignitana-ab-publishes-q2-2024-interim-report,c4027194</link><guid isPermaLink="false">cision4885148</guid><description><![CDATA[Advancing forward with clear vision

Financial highlights Q2 2024

  · Net Sales amounted to 21.8 MSEK (21.1), an increase of 4 percent over the same quarter in 2023.
  · Operating Result amounted to -11.0 MSEK (-4.7).
  · Net Result after financial items amounted to -11.5 MSEK (-4.7).
  · EBITDA for the second quarter were negative at -7.0 MSEK (-0.9).
  · Earnings per share were -0.14 SEK (-0.07).
  · Cash Balance amounted to 7.0 MSEK (5.4).
  · Average Daily Treatment Revenue (ADTR)* was 223 TSEK (241) in the quarter.

Business highlights during the period

  · Dignitana]]></description><pubDate>Thu, 22 Aug 2024 06:00:00 GMT</pubDate></item></channel></rss>